WKN DE: A40ZVN / ISIN: DE000A40ZVN7

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV		Knock-Outs
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime
Kurs + Chart
Chart (groß)
Times + Sales
Chartvergleich
Börsenplätze
Realtime Push
Orderbuch
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Aktion
Portfolio
Watchlist

Viromed Medical Times and Sales (STU)

Zeit	Kurs	Umsatz (Stk)	Umsatz grafisch
Times and Sales Zur Zeit stehen keine Daten zur Verfügung

Kursrückgang	Kursanstieg	keine Kursänderung
(Balkenlänge beschreibt das Umsatzvolumen)

Nachrichten zu Viromed Medical AG

16.10.26		EQS-DD: Viromed Medical AG: Heike Perbandt, Verkauf
16.10.26		EQS-DD: Viromed Medical AG: Heike Perbandt, sell
07.10.26		EQS-DD: Viromed Medical AG: Heike Perbandt, Verkauf
07.10.26		EQS-DD: Viromed Medical AG: Heike Perbandt, sell
07.10.26		EQS-DD: Viromed Medical AG: Heike Perbandt, sell
07.10.26		EQS-DD: Viromed Medical AG: Heike Perbandt, Verkauf
30.09.26		EQS-Adhoc: Viromed Medical AG: Study on cold plasma application in the lung accepted for publication by an internationally leading medical journal
30.09.26		EQS-Adhoc: Viromed Medical AG: Studie zur Kaltplasma-Anwendung in der Lunge von einem international führenden medizinischen Fachjournal zur Veröffentlichung angenommen

Analysen zu Viromed Medical AG

Weitere Meldungen

02:27		Gas supply cut from Indonesia accounts for less than 2% of Singapore’s daily gas demand: EMA
02:17		Audi to Build Factory in Georgia, Trump Says
02:02		Is the AI Bubble About to Burst? Plus, Apple Bets on Doorbells.
02:00		Co-operate to avoid being hostage to geopolitics, Australia tells ‘middle powers’
02:00		Co-operate to avoid being hostage to geopolitics, Australia tells ‘middle powers’
02:00		SpaceX’s $1 Trillion Revenue Ambition: Can Elon Musk Deliver?
02:00		Is Now a Good Time to Buy Lockheed Martin?
01:51		Nigeria: Tinubu launches reelection bid amid economic woes
01:50		Should You Ignore the SpaceX Hype and Buy Rocket Lab Instead?
01:00		Jemperli (dostarlimab) data show 76% of patients with MSI-H/dMMR locally advanced rectal cancer achieved a complete response
01:00		Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
00:52		Booking vs. Chewy: Do Pet Treats or Plane Tickets Make for a Better Stock in 2026?
00:41		Is Berkshire Bending the Rules With Bending Spoons?
00:32		Advance Auto Parts vs. Etsy: Which Consumer Stock Is a Better Buy in 2026?
00:30		Stock-Split Watch: Is Palantir Next?
24.10.26		Booking vs. Five Below: Is the Travel Giant or Specialty Retailer the Better Stock to Buy in 2026?
24.10.26		Netflix Stock Has Always Overcome the Odds. Has It Finally Hit a Wall?
24.10.26		Before You Buy the Vanguard S&P 500 ETF, There's 1 Sneaky Risk Investors Should Know
24.10.26		Here's How Many Shares of Apple Stock You'd Need for $100 in Yearly Dividends
24.10.26		GE Vernova Stock Fell 11% in a Day. Here's What I Think It Could Be Worth by 2030.
24.10.26		Booking vs. GameStop: Is Travel or Collectibles the Better Value Creator in Stocks?
24.10.26		Elon Musk Just Gave Fantastic News for Nvidia Investors
24.10.26		Could Buying XRP Today Set You Up for Life?
24.10.26		Alibaba vs. Booking: Which Travel Provider Stock Is a Better Buy in 2026?
24.10.26		Ukraine: Starlink satellite speeds restored to normal
24.10.26		The Nasdaq Just Had Its Worst Day in 4 Months. Here's the Level That Would Signal a Correction, and What History Says Investors Can Do About It.
24.10.26		Oklo Is Down 61% This Year Despite a Real Technical Milestone. Here's the Disconnect Between the Stock and the Science.
24.10.26		Blackstone: 3 Key Takeaways for Long-Term Investors
24.10.26		Realty Income Stock Climbs Back as Treasury Yields Retreat, Yet Challenges Persist
24.10.26		Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.
24.10.26		Elon Musk Is ‘Okay With Being Disliked’ — and He Knows Exactly Where His $985 Billion Fortune Is Going
24.10.26		Union Pacific Corporation: 3 Key Takeaways for Long-Term Investors
24.10.26		Advance Auto Parts vs. Booking Holdings: Which Consumer Stock Is a Better Buy in 2026?
24.10.26		Top Blockchains Continue to See Rapid Growth in AI Agent Payments. This Is the 1 Crypto You Need to Buy Right Now.
24.10.26		XRP Price Faces Downside Risk Despite Rising ETF Inflows and RLUSD Growth
24.10.26		Advance Auto Parts vs. Dick's Sporting Goods: Are Consumers Focusing on Car Repair or Exercise More in 2026?
24.10.26		5 of the Fastest-Growing Stocks in the Market
24.10.26		Down Roughly 50% From Its Highs, Is Netflix Stock Finally a Buy?
24.10.26		Is Nike Still a Growth Stock? Here's the Answer.
24.10.26		Broadcom vs. Dell Technologies: Which Stock Is AI Powering to Be a Better Buy in 2026?
24.10.26		Airbnb vs. Chewy: Do Pets or Places Power One Stock More than the Other?
24.10.26		Bloom Energy Raised Its 2026 Forecast for the Third Time. Is the Stock a Buy More Than a Third Below Its Record?
24.10.26		Apple Joins Nvidia in the $5 Trillion Club. Here's Which Stock I Think Can Get to $10 Trillion First.
24.10.26		Safe Haven Trade: SCHD Outperforms VOO and QQQ as AI Bubble Fears Mount
24.10.26		Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy?
24.10.26		Inflation Is Running Hotter Than Expected. That Could Be Bullish for Bitcoin.
24.10.26		Honeywell Technologies: 3 Key Takeaways for Long-Term Investors
24.10.26		Six Flags to Add Seatbelts on Roller Coasters After Rider’s Death
24.10.26		Why Appian Stock Surged 24.2% This Week
24.10.26		Conifer Management Buys $16.9 Million Group 1 Automotive Shares. What Does This Mean for Investors?

Zurück | 1 | 2 | Weiter

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Weitere Aktien: Jinhai Medical Technology TO Books Upside Gold SyntheticMR AB Registered Shs Issue 2026-1 Devonian Health Group

Kontakt - Impressum - Werbung - Barrierefreiheit

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2026 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 81% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	25.10.2026 10:34
Kaufwert:	EUR
	Hinzufügen Speichern

Viromed Medical Aktie

WKN DE: A40ZVN / ISIN: DE000A40ZVN7

Viromed Medical Times and Sales (STU)

Times and Sales

Nachrichten zu Viromed Medical AG

Analysen zu Viromed Medical AG

Weitere Meldungen